

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

4.2 Most important symptoms and effects, both acute and delayed

Risks : Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Sulphur oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.
 Do not breathe dust.
 Do not swallow.
 Avoid contact with eyes.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents

Ezetimibe Granules Formulation

Version 2.6 Revision Date: 09.04.2021 SDS Number: 1563976-00009 Date of last issue: 10.10.2020
Date of first issue: 18.04.2017

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m ³	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				
		STEL OEL-RL (Dust)	20 mg/m ³	ZA OEL
Further information: Recommended Limit				
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m ³
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium n-dodecyl sulfate	Fresh water	0,176 mg/l
	Marine water	0,018 mg/l
	Sewage treatment plant	1,35 mg/l
	Fresh water sediment	6,97 mg/kg dry weight (d.w.)
	Marine sediment	0,697 mg/kg dry weight (d.w.)
	Soil	1,29 mg/kg dry weight (d.w.)

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

8.2 Exposure controls**Engineering measures**

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye protection : Wear the following personal protective equipment:
Safety goggles

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance : granular

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Upper explosion limit / Upper flammability limit : No data available

SAFETY DATA SHEET



Ezetimibe Granules Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

10.4 Conditions to avoid

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Ezetimibe:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 5.000 mg/kg
LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2.000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1.000 - < 2.000 mg/kg
Application Route: Intraperitoneal

Sodium n-dodecyl sulfate:

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Ezetimibe:**

Species : Rabbit
Result : No skin irritation

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Sodium n-dodecyl sulfate:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ezetimibe:**

Species : Rabbit
Result : No eye irritation

Sodium n-dodecyl sulfate:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ezetimibe:**

Test Type : Maximisation Test
Species : Guinea pig
Result : negative

Sodium n-dodecyl sulfate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Ezetimibe:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative

Test Type: Chromosomal aberration

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Ezetimibe:**

Species : Rat, female
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Rat, male
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Mouse
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Sodium n-dodecyl sulfate:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative
Remarks : Based on data from similar materials

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Reproductive toxicity

Not classified based on available information.

Components:**Ezetimibe:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1.000 mg/kg body weight Result: No effects on fertility, No fetotoxicity
Effects on foetal development	:	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight Result: No adverse effects
		Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight Result: No adverse effects

Sodium n-dodecyl sulfate:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Ezetimibe:**

Species	:	Dog
NOAEL	:	1.000 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Rat
---------	---	-----

Ezetimibe Granules Formulation

Version 2.6 Revision Date: 09.04.2021 SDS Number: 1563976-00009 Date of last issue: 10.10.2020
Date of first issue: 18.04.2017

NOAEL : 1.500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 1 yr
Remarks : No significant adverse effects were reported

Sodium n-dodecyl sulfate:

Species : Rat
NOAEL : 488 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Ezetimibe:**

Not applicable

Experience with human exposure**Components:****Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

SECTION 12: Ecological information**12.1 Toxicity****Components:****Ezetimibe:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0,125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

-
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- Toxicity to microorganisms : EC50 : > 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
- NOEC : 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
- Toxicity to fish (Chronic toxicity) : NOEC: 0,051 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
- NOEC: 4 mg/l
Exposure time: 7 d
Species: Cyprinodon variegatus (sheepshead minnow)
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0,282 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Remarks: No toxicity at the limit of solubility
- M-Factor (Chronic aquatic toxicity) : 1
- Sodium n-dodecyl sulfate:**
- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

plants	Exposure time: 72 h
	NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l Exposure time: 72 h
Toxicity to microorganisms	: EC50 : 135 mg/l Exposure time: 3 h
Toxicity to fish (Chronic toxicity)	: NOEC: >= 1,357 mg/l Exposure time: 42 d Species: Pimephales promelas (fathead minnow)
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0,88 mg/l Exposure time: 7 d Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability**Components:****Ezetimibe:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 6,8 % Exposure time: 28 d
------------------	--

Stability in water	: Hydrolysis: 50 %(4,5 d) Method: OECD Test Guideline 111
--------------------	--

Sodium n-dodecyl sulfate:

Biodegradability	: Result: Readily biodegradable. Biodegradation: 95 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---

12.3 Bioaccumulative potential**Components:****Ezetimibe:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Exposure time: 97 d Bioconcentration factor (BCF): 173 Method: OECD Test Guideline 305
-----------------	---

Partition coefficient: n-octanol/water	: log Pow: 4,36
--	-----------------

Sodium n-dodecyl sulfate:

Partition coefficient: n-octanol/water	: log Pow: 0,83
--	-----------------

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

12.4 Mobility in soil**Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4,35
Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

(Ezetimibe)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe)

IATA : Environmentally hazardous substance, solid, n.o.s.
(Ezetimibe)

14.3 Transport hazard class(es)

ADN : 9

ADR : 9

RID : 9

IMDG : 9

IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

SAFETY DATA SHEET



Ezetimibe Granules Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Packing instruction (passenger aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Full text of H-Statements

H302 : Harmful if swallowed.
 H315 : Causes skin irritation.
 H318 : Causes serious eye damage.
 H410 : Very toxic to aquatic life with long lasting effects.
 H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
 Aquatic Chronic : Long-term (chronic) aquatic hazard
 Eye Dam. : Serious eye damage
 Skin Irrit. : Skin irritation
 ZA OEL : South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
 ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit
 ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

SAFETY DATA SHEET



Ezetimibe Granules Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1563976-00009	Date of first issue: 18.04.2017

Classification of the mixture:

Aquatic Chronic 2

H411

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN